Background: Protein kinase C beta (PKCb), a pivotal enzyme in B-cell signaling and survival, is overexpressed in most cases of mantle cell lymphoma (MCL). Activation of PI3K/AKT pathway is involved in pathogenesis of MCL. Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through PKCb/PI3K/AKT pathways, induces apoptosis, reduces proliferation, and suppresses tumor-induced angiogenesis.
MCL and diffuse large B-cell lymphoma (DLBCL) [19, 20] . PKCb was found to be overexpressed in fatal, treatmentrefractory DLBCL in both gene expression profiling [21] and immunohistochemistry [22] experiments and was found to be associated with shortened survival [22] . Independent immunohistochemical (IHC) studies have shown that PKCb is expressed in 90% of all MCL samples [23] . These data indicate that PKCb is a rational target in MCL since inhibition of PKCb may impact both the microvasculature and tumor cell growth.
Enzastaurin HCl is an acyclic bisindolylmaleimide that was initially developed as an ATP-competitive, selective inhibitor of PKCb [24, 25] . The compound also inhibits signaling through the PI3Kinase/AKT pathway [25] , a key regulator of apoptosis [26, 27] , also reported to be deregulated in many cases of lymphoid malignancies, including MCL [28, 29] . In vitro preclinical assays show 95% plasma protein binding and an IC90 of 70 nM for PKCb (Upstate kinase profilerä data) and other PKC isoforms. Based on these data, a plasma concentration of 1400 nM is predicted to be adequate to inhibit most PKC isoforms. In preclinical studies, enzastaurin induced apoptosis and inhibited the proliferation of several cancer cell lines including DLBCL [27, 30] and has demonstrated antiangiogenic, antiproliferative, and proapoptotic effects in xenograft studies and the rat corneal micropocket assay [27, 31] . Based on plasma exposures and safety data from a phase I study, 525 mg of daily, oral enzastaurin was the recommended dose [32] . At this dose, in multiple phase I studies, enzastaurin was generally well tolerated in patients with advanced cancers, both as a single agent and in combination with cytotoxic therapy [32] [33] [34] . In a phase II trial in patients with advanced relapsed/refractory DLBCL, enzastaurin showed a favorable toxicity profile and several patients achieved prolonged disease stabilization, including 4 of 55 patients who continued treatment for 2-4 years [35] .
Because of the need for novel, effective agents in the treatment of MCL, the role of PKCb and the PI3Kinase/AKT pathway in MCL, and the preclinical and clinical data obtained with enzastaurin, a phase II trial of enzastaurin in MCL was initiated. The primary objective of this study was to estimate the rate of freedom from progression for at least three cycles. Secondary objectives included the evaluation of objective response rate, progression-free survival (PFS) time, overall survival time, safety, immunohistochemistry, and pharmacokinetics.
patients and methods

eligibility criteria
Adult patients (age ‡ 18 years) with a pathologically confirmed diagnosis of MCL who had relapsed/refractory disease were eligible. Patients could not have received more than four prior treatment regimens. Rituximab, used alone, was not considered a separate prior regimen. Other entry criteria included evaluable (blood and bone marrow disease only) or bidimensionally measurable disease; an estimated life expectancy of at least 12 weeks; a performance status of zero to two on the Eastern Cooperative Oncology Group (ECOG) scale; and adequate organ function including total bilirubin £1.5 · upper limit of normal (ULN), alanine transaminase and aspartate transaminase £2.5 · ULN, and serum creatinine £2.0 · ULN. Patients were excluded if they had known central nervous system or leptomeningeal involvement; human immunodeficiency virus-associated lymphoma; a serious concomitant disorder (such as an active bacterial, fungal, or viral infection); an absolute neutrophil count £0.5 · 10 9 /l and platelets £50 · 10 9 /l; uncorrected potassium <3.4 mmol/l; clinically significant cardiac abnormalities, including myocardial infarction that occurred < 6 months before inclusion, symptomatic angina pectoris, or cardiac failure not controlled by medication; or an inability to swallow tablets. The protocol was approved by the Institutional Review Board of each participating institution. Written informed consent was obtained from each patient before study enrollment. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was consistent with good clinical practices and applicable laws and regulations.
study design and treatment plan
In this phase II, multicenter, open-label, single-arm study, we planned to enroll up to 60 patients using a two-stage design. Twenty patients were entered in the first stage of the study. If at least three patients were progression free after three cycles, accrual was planned to continue until a total of 60 patients were enrolled. If at least 11 of the 60 enrolled patients were progression free after three cycles, it would be concluded that the regimen is worthy of further study. Patients received 500 mg (100-and 200-mg tablets, equivalent to 525 mg capsules) oral enzastaurin once daily, in the morning, during each 28-day cycle of therapy for a planned treatment duration of up to six treatment cycles. Treatment continued until unacceptable toxicity or progressive disease occurred. No other chemotherapy, immunotherapy, experimental medications, or radiation therapy was permitted while patients were onstudy.
baseline and treatment assessments
Disease status was assessed by physical examination at baseline and before every cycle for palpable or visible lesions and at baseline and after every third cycle for measurable disease using radiological imaging (computed tomography scan of chest, neck, thorax, abdomen, and pelvis). Unilateral bone marrow aspirate and/or biopsy (for patients with a history of bone marrow involvement) and cytology of peripheral blood lymphocytes (for patients with blood involvement) were carried out at baseline and after every third cycle. ECOG performance status and B symptoms (fever >38°C, weight loss >10% of body weight in the preceding 6 months, and night sweats) were assessed at baseline and before every cycle. Serum chemistry and hematology laboratory tests were carried out at baseline and before each cycle. Electrocardiogram was carried out at baseline and in cycles 1 and 2. Prognostic risk factors were classified at baseline using the International Prognostic Index (IPI). Poststudy follow-up included evaluation of performance status, tumor measurements and imaging studies, and poststudy drug treatment.
Response for patients with measurable disease was recorded using standardized response criteria for NHLs [36] . Objective response was defined as complete response (CR) or partial response (PR). Freedom from progression was defined as CR, PR, or stable disease (SD) for ‡3 cycles. SD was defined as less than partial response, with no findings consistent with progressive disease and no appearance of new lesions. The rate of freedom from progression was computed as the number of patients documented to be progression free after three cycles of enzastaurin divided by the number of treated patients. PFS time was defined as the time from the date of enrollment to the first date of documented disease progression or death due to any cause, whichever occurred first. Overall survival time was defined as the time from the date of enrollment to the date of death due to any cause. CRs or PRs were confirmed with scans carried out at least 4 weeks after the initial response. All enrolled patients were assessed before each cycle for treatment-related toxicity using Common Toxicity Criteria, version 2.0 [37].
original article Annals of Oncology pharmacokinetic analysis
Plasma samples for pharmacokinetic evaluation were collected between 1-4 and 4-8 h postdose on day 1 of cycle 1; predose, 2-4 and 6-8 h postdose on day 1 of cycle 2; and predose and 2-8 h postdose on day 1 of cycle 3. Samples were assayed for enzastaurin and its metabolites using highperformance liquid chromatography-tandem mass spectrometry. A population pharmacokinetic approach was used to analyze the sparse plasma concentration versus time data in individual patients. Data from all patients were combined and analyzed using nonlinear mixed effect modeling.
IHC analysis of PKCb expression
Tumor samples at baseline were obtained from patients for IHC staining of PKCb expression. Immunohistochemistry was carried out at Ventana Medical Systems, Inc. (Tucson, AZ), using a mouse monoclonal antibody, specific to the PKCb2 isoform (Sigma, catalog #P2584, clone PK-B26) and a mouse immunoglobulin (VMSI, Catalog No. 760-2014) as negative control [38] . Staining intensity was measured on a semiquantitative scale of 0 (or negative) to 3 (high intensity). The final score combined the components of staining intensity and the percentage of positive cells and was defined as Table 1 shows the baseline patient characteristics. Thirty-nine (65%) patients were diagnosed with MCL at least 3 years before study enrollment. Central pathology review carried out for confirmation of MCL revealed that one patient had a diagnosis of chronic lymphocytic leukemia. This patient was not included in the survival analyses. Additional pathology data available from 23 patient samples showed that 20 patients had classical morphology and two had the blastic variant. Four patient samples exhibited a high proliferation rate with Ki67 ‡40%.
study drug administration
All 60 enrolled patients received at least one dose of enzastaurin. There were five dose omissions due to adverse events not related to enzastaurin. Two patients discontinued enzastaurin due to possibly drug-related adverse events (diarrhea and syncope).
clinical toxic effects
All 60 enrolled patients were evaluated for safety. The most common toxic effects observed were fatigue (in five patients, grade £ 2) and diarrhea (in three patients with grade 1 and one patient with grade 3). Other drug-related toxic effects observed in more than one patient were myalgia, sweating, chromaturia (orange-red color of urine due to the color of the drug tablet), and anorexia (all grade 1). Grade 2 toxic effects were fatigue (in two patients) and thrombocytopenia (in one patient). Grade 3 toxic effects reported were anemia, diarrhea, dyspnea, syncope, hypotension, and vomiting (in one patient each). No enzastaurin-related grade 4 toxicity or death occurred.
efficacy
Of the 60 study patients, 22 [37%, 95% confidence interval (CI) 25% to 49%] were free from progression (FFP) for ‡3 cycles (2.8 months). Six of the 22 patients were FFP for >6 months, which was similar to the time to new treatment after the previous conventional chemotherapy regimen (Table 2) . Two patients were FFP for >23 months. The median PFS time was 2 months (95% CI 1.45-2.66 months) (Figure 1 ). The median PFS time for the 22 patients who were FFP for ‡3 cycles was 4.3 months (95% CI 3.29-5.55 months). The median overall survival time in this study was 22 months (range 0.9-23+ months). A comparison of the baseline characteristics of the patients who were FFP for ‡3 cycles and patients who did not meet the primary end point revealed that the latter group of patients had elevated lactate dehydrogenase (LDH) levels (42% versus 14%) and lesions ‡5 cm (53% versus 32%) ( Table 3) .
No CRs or PRs were observed in this study. One patient, who had relapsed after prior therapy with high-dose cytosine arabinoside, achieved a minor response (a 25%-50% reduction in lesion size).
pharmacokinetics Pharmacokinetic data were available on 56 patients. In these patients, the average steady-state concentration (C av,ss ) was 627 nmol/l (74.4% coefficient of variation [CV]) for enzastaurin (Table 4 ). There were no differences in steady-state enzastaurin exposures between patients who met the primary end point (FFP for ‡3 cycles), all patients, and patients who were FFP for >6 months (Table 4) . immunohistochemistry Samples were available from 18 patients for PKCb immunohistochemistry: 14 (78%) samples had a score ‡100 and a staining intensity ‡2 (high intensity indicating overexpression) and four samples had a score <100 and a staining intensity £1 (data not shown). Of the 14 patients who had PKCb overexpression, seven patients met the primary end point (FFP for ‡3 cycles) and seven did not (Table 3) .
discussion
Here we report the results from the first study of the PKCb inhibitor enzastaurin in patients with MCL. Twenty-two of 60 (37%) patients enrolled achieved the primary end point of freedom from progression for ‡3 cycles. Although overall response rate remains the usual primary end point to evaluate anticancer drugs, other parameters such as freedom from progression are increasingly being used to evaluate new targeted therapeutic agents. These agents, with their novel mechanism of action, have a predominantly inhibitory effect on tumor growth, unlike traditional cytotoxic agents, which cause tumor shrinkage [39] . Given the characteristics of enzastaurin and its typical profile in the class of targeted therapeutics, freedom from progression for ‡3 cycles was considered a pertinent efficacy end point in this population of patients with relapsed/ refractory MCL, whose prognosis is generally poor. In this [35] and are consistent with enzastaurin's activity as a tumor growth inhibitory agent that lacks direct tumor cytotoxicity. Of the patients who were FFP for >6 months, two patients had Ki67 ‡40% and two patients were ‡80 years of age. Enzastaurin was well tolerated in this study. No grade 4 toxic effects were reported. The majority of patients did not experience any adverse event. There were only six grade 3 toxic effects, each of which occurred in only one patient. Anemia (in one patient) was the only grade 3 hematological toxicity reported. No significant hepatobiliary, cardiac, or severe bone marrow toxicity was observed. The safety profile of enzastaurin indicates that it can be used in a maintenance setting, even in elderly patients who typically have severe toxic effects following aggressive chemotherapy. Interestingly, in addition to the low toxicity, the duration of freedom from progression after enzastaurin in the six patients who were FFP for >6 months was comparable to the time between the last previous conventional chemotherapy regimen and initiation of enzastaurin.
The plasma exposures of enzastaurin in this study were comparable to those obtained with similar doses of enzastaurin in the recently reported phase I trial [32] and in patients with DLBCL. The mean steady-state concentrations for total analytes were >1000 nmol/l, the concentration at which enzastaurin inhibited PKCb and additional PKC isoforms in in vitro kinase screens. This indicates that PKCb inhibition may, at least in part, contribute to enzastaurin activity. Plasma exposures of enzastaurin and total analytes are unlikely to explain the differences observed in the duration of freedom from progression since enzastaurin exposures were not different in the group of patients who achieved long-term freedom from progression (more than six cycles) compared with patients who did not achieve the primary end point of freedom from progression for ‡3 cycles.
In order to identify patients who are most likely to benefit from enzastaurin treatment, molecular targets and markers predictive of enzastaurin treatment outcome need to be identified. IHC analysis of PKCb expression in a small patient sample indicated that the enzyme was highly expressed in most patients. The fact that we did not observe high PKCb expression in all patients, as was reported in a previous study [25] , may be attributed to differences in the antibody used previously [35] and in the quantification of staining intensity. In our study, PKCb overexpression was quantified as a composite of the staining intensity and the number of cells. Due to the small number of tumor samples and the lack of pre-enzastaurin treatment biopsies, it was difficult to draw any conclusions regarding a correlation of PKCb overexpression with either the disease characteristics or survival. Lastly, because PI3K/AKT is also implicated in MCL and since enzastaurin inhibits both PKC and AKT pathways, analysis of downstream proteins, such as phosphorylation of GSK-3b and S6kinase, in addition to PKC expression, is recommended in future clinical studies to correlate the activation of these enzymes with clinical outcome.
Data obtained from this study indicate that patients with nonbulky disease and normal LDH had SD for the longest duration. Patients who had disease stabilization for >6 months on enzastaurin also had long time to progression on the previous and mainly first-line therapy, which indicates they may belong to the subgroup of indolent MCL [40] .
However, all patients had relapsed and were identified as requiring further treatment. Given that the optimal management of relapsed MCL remains quite challenging, with no identified standard of care, it is noteworthy that these 
